Targeted therapy, mostly represented by BRAF inhibitors, shows efficacy in the treatment of BRAF mutated metastatic melanoma when administered as single agents or in combination with MEK inhibitors [4]. This evidence concerns the gene BRAF and metastatic melanoma.